Document is current

Article History

Received: 11 February 2025

Accepted: 4 April 2025

First Online: 28 April 2025

Declarations

:

: There are no conflicts of interest related to the study design or its results. Christian Maurer declares travel grants from Mundipharma, Amgen, Servier Deutschland GmbH, Abbvie, and consulting fees from Abbvie, Celgene/BMS and Pfizer. He received honoraria for lectures from Daiichi Synkyo and Novartis. Elisa Agostinetto declares advisory board and/or honoraria from Eli Lilly, Sandoz, AstraZeneca, Abscint; she declares research grant to her Institution from Gilead, meeting/travel grants from Novartis, Roche, Eli Lilly, Genetic, Istituto Gentili, Daiichi Sankyo, and AstraZeneca (all outside the present work). Lieveke Ameye declares no conflict of interests. Matteo Lambertini declares advisory role for Roche, Lilly, Novartis, Astrazeneca, Pfizer, Seagen, Gilead, MSD and Exact Sciences and speaker honoraria from Roche, Lilly, Novartis, Astrazeneca, Pfizer, Sandoz, Libbs, Daiichi Sankyo, Knight, Ipsen and Takeda, travel grants from Gilead and Daiichi Sankyo, and research support (to the Institution) from Gilead outside the submitted work. Noam Ponde is an employee of IQVIA Biotech. Mariana Brandão declares advisory board fees and/or honoraria from Roche/GNE, Janssen, BMS, Amgen, Takeda, Pierre-Fabre, travel grants from Roche/GNE, Sanofi and Takeda and research grants to her institution from Roche/GNE, AstraZeneca, GSK/Novartis and Servier. Francesca Poggio declares advisory board fees and/or honoraria from EliLilly, Novartis, AstraZeneca, Daichii Sankyo, and Seagen, meeting travel from Gilead, Pfizer, Pierre Fabre. Arlindo Ferreira declares honoraria and/or advisory board fees from Daiichi Sankyo, Gilead, Merck Sharp & Dohme, Novartis, Roche and travel grants from Roche. He is an employee of Resilience. Rachel Schiff declares research funding/grants to her institution (past and present) from AstraZeneca, GlaxoSmithKline, Puma, Biotechnology Inc, and Gilead Sciences, speaker honoraria and/or travel expenses from Binaytara Foundation and Dava Oncology, LP, and advisory board fees from Eli Lilly Daiichi Sankyo (Ad hoc), and Macrogenics. She declares royalties from UpToDate, is co-inventor in the Baylor College of Medicine’s pending patent application # PCT/US21/70543 (Methods for breast cancer treatment and prediction of therapeutic response), and has served as a member of the SABCS (Breast cancer symposium) Faculty/Planning Committees. Carmine De Angelis declares advisory role for Roche, Lilly, Novartis, AstraZeneca, Pfizer, Seagen, Daichi Sankyo, Gilead, and GSK and speaker honoraria from Roche, Lilly, Novartis, Pfizer, Seagen, GSK, Gilead, and Daiichi Sankyo. He declares travel grants from Gilead and research support (to the Institution) from Novartis, GILEAD, and Daiichi-Sankyo outside the submitted work. He is co-inventor in the Patent application # PCT/US21/70543 (Methods for breast cancer treatment and prediction of therapeutic response). Richard D Gelber declares institutional funding from Roche, AstraZeneca, Merck. Susan Dent declares grant funding and honararia from Novartis. Christoph Thomssen declares advisory role and/or speaker honoraria from Amgen, AstraZeneca, Aurikamed GmbH, Daiichi Sankyo, Gilead, Hexal, Joerg Eickeler, Lilly, Medupdate GmbH, Medicultus Kassel GmbH, MSD, Novartis, Onkowissen TV, Pfizer, Roche, Roland Berger GmbH, Seagen, Streamedup GmbH. Martine Piccart is board member from Oncolytics and declares honoraria from AstraZeneca, Gilead, Lilly, Menarini, MSD, Novartis, Pfizer, Roche-Genentech, Seattle Genetics, Seagen, NBE Therapeutics, Frame Therapeutics. She declares institutional research grants from AstraZeneca, Lilly, Menarini, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon, Gilead. Evandro de Azambuja declares honoraria and/or advisory board from Roche/GNE, Novartis, SeaGen, Zodiac, Libbs, Pierre Fabre, Lilly, Astra-Zeneca, MSD, Gilead Sciences; Travel grants from Roche/GNE and AstraZeneca; he declares research grant to his institution from Roche/GNE, AstraZeneca, and GSK/Novartis, Gilead Sciences; he is ESMO director of Membership 2023–2024 and BSMO President 2023-2026.

: Here we present an exploratory analysis of the APHINITY trial. The institutional review board at each participating center approved the APHINITY trial protocol.

: All patients in APHINITY provided written informed consent.

: Not applicable as the manuscript does not contain any individual person’s data.